New Jersey Medicaid spending on GLP-1 drugs

How much did New Jersey Medicaid spend on GLP-1 drugs like Ozempic and Mounjaro in 2025?

Pharmacies were reimbursed at least $151.4 million for GLP-1 drugs paid through New Jersey Medicaid in 2025, across at least 165,667 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 135 rows of 289, so these figures are floors.

Pharmacies were reimbursed at least $27.4 million for GLP-1 drugs paid through New Jersey Medicaid in 2026 (quarter 1 only, as posted so far), across at least 28,333 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 36 rows of 74, so these figures are floors.

By year and ingredient

2020at least $4,523,616No dataat least $19,987,839at least $11,680,326at least $9,593,330at least $55,724at least $320,544at least $121,700at least $46,283,080
2021at least $9,858,865No dataat least $22,523,152at least $17,290,255at least $13,691,204at least $8,662at least $387,193at least $106,877at least $63,866,209
2022at least $19,971,836at least $327,107at least $24,909,159at least $27,851,010at least $19,906,124Suppressedat least $462,245at least $93,740at least $93,521,221
2023at least $36,488,760at least $5,658,402at least $23,644,857at least $35,664,159at least $18,900,875No dataat least $515,692$66,220at least $120,938,964
2024at least $58,354,143at least $22,160,123at least $13,523,843at least $13,219,766at least $20,487,873No dataat least $326,853Suppressedat least $128,072,602
2025at least $72,595,390at least $47,977,201at least $13,486,644at least $12,287,395at least $4,964,863No data$133,707Suppressedat least $151,445,199
2026 (Q1)at least $11,248,347at least $10,501,277at least $1,523,097at least $4,107,437No dataNo dataat least $19,242Suppressedat least $27,399,401

By product, 2025

Ozempicat least $64,709,299at least 64,8094 of 32
Rybelsusat least $2,783,849at least 2,7645 of 17
Wegovyat least $5,102,241at least 3,8298 of 28
Mounjaroat least $41,097,412at least 37,88043 of 67
Zepboundat least $6,879,789at least 6,38518 of 38
Liraglutide (generic name listing)at least $13,486,644at least 30,99518 of 42
SaxendaSuppressedSuppressed3 of 3
VictozaSuppressedSuppressed9 of 9
Trulicityat least $12,287,395at least 12,74617 of 36
Bydureonat least $4,964,863at least 6,1073 of 6
ByettaSuppressedSuppressed1 of 1
Exenatide (generic name listing)SuppressedSuppressed2 of 2
Soliqua$133,7071520 of 4
XultophySuppressedSuppressed4 of 4

By quarter, 2025

Q1 2025at least $33,197,875at least 36,68235 of 71
Q2 2025at least $35,539,515at least 39,11133 of 71
Q3 2025at least $39,513,592at least 43,51233 of 71
Q4 2025at least $43,194,215at least 46,36234 of 76

By quarter, 2026 (posted so far)

Q1 2026at least $27,399,401at least 28,33336 of 74

The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:

“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”

Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”

CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.

Fee-for-service and managed care rows are added together. Other states: Medicare and Medicaid spending on GLP-1 drugs.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.